Keta Med Lab / www.ketamedlab.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
Here's the summary: **FDA Warning Letter to Keta Med Lab, June 23, 2026 (MARCS-CMS 725154)** The FDA Center for Drug Evaluation and Research (CDER) cited Keta Med Lab and www.ketamedlab.com for introducing unapproved and misbranded ketamine drug products into interstate commerce, including ketamine liquid, ketamine troches for depression, and esketamine nasal spray, violating sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The agency stated these products lack FDA approval despite FDA-approved versions existing for some forms, and that unapproved injectable drugs pose risks including contamination, incorrect dosing, and serious infections such as sepsis. FDA requested Keta Med Lab cease offering unapproved and misbranded drugs to U.S. consumers, warning that failure to address violations may result in seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: Keta Med Lab
**Company and Violations**
Keta Med Lab, operating at www.ketamedlab.com, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on June 23, 2026. The FDA identified that the company was introducing unapproved and misbranded ketamine drug products into interstate commerce via its website. The agency documented violations during a February 26, 2026 review and expressed concern that internet availability of unapproved ketamine products creates serious consumer safety risks, particularly given the lack of medical supervision and the potential for serious adverse events associated with injectable formulations.
**Regulatory Citations and Meaning**
The FDA cited violations under sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331 and 352-355). Section 505(a) prohibits introducing new drugs without FDA approval; sections 502(f)(1) and 503(b)(1) require adequate directions for use and prescription-only status for drugs unsafe without practitioner supervision. The specific products cited included ketamine liquid, ketamine troches marketed for depression, and esketamine nasal spray. The letter emphasized that FDA-approved alternatives exist (KETALAR for anesthesia; SPRAVATO for treatment-resistant depression under a REMS program), yet the unapproved versions lack these safety oversight mechanisms.
**Timeline and Industry Monitoring**
The company must cease offering these products immediately. Compliance officers in pharmaceutical e-commerce should monitor for FDA follow-up actions including potential seizures or injunctions if violations continue. Peers should review their own websites for similar direct therapeutic claims, ensure proper prescription-only gating, and verify that any ketamine-related offerings remain within approved indications and distribution channels.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Keta Med Lab / www.ketamedlab.com MARCS-CMS 725154 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Keta Med Lab / www.ketamedlab.com United States info@ketamedlab.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725154 To Keta Med Lab: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketamedlab.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.ketamedlab.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.ketamedlab.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.ketamedlab.com, FDA Establishment Identifier (FEI) 3043543982, on February 26, 2026. Violations of the Federal Food, Drug, and Cosmetic Act On your website at internet addres…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Keta Med Lab / www.ketamedlab.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Keta Med Lab / www.ketamedlab.com as of 2026-07-07. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Keta Med Lab / www.ketamedlab.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-keta-med-lab-www-ketamedlab-com-2026-06-23-unapproved-drug
"Keta Med Lab / www.ketamedlab.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-keta-med-lab-www-ketamedlab-com-2026-06-23-unapproved-drug.
Argus HQ Research. "Keta Med Lab / www.ketamedlab.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-keta-med-lab-www-ketamedlab-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_keta_med_lab_www_ketamedlab_com_2026_06_23_unapproved_drug_2026,
title = {Keta Med Lab / www.ketamedlab.com — FDA Warning Letter, 2026-06-23: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-keta-med-lab-www-ketamedlab-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}